Related Experiment Video
Updated: Jun 23, 2026
10:40
Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model
Published on: August 4, 2012
12.7K
Altered Liver Biochemistry and Mortality in Patients Hospitalized With COVID-19
Felipe A Muñoz Rossi1, Diana Marcela Gallo Orjuela2,3, Ana Maria Guaiquil4
1Internal Medicine, National University of Colombia, Bogota, COL.
Cureus
|March 18, 2024
Summary
Elevated liver function tests in hospitalized COVID-19 patients are common and linked to a significantly higher risk of death. Early detection of these hepatic profile alterations is crucial for better patient outcomes.
Area of Science:
- Hepatology
- Infectious Diseases
- Critical Care Medicine
Background:
- COVID-19, caused by SARS-CoV-2, is a major global health challenge.
- Organ damage beyond the lungs in COVID-19 requires further investigation.
- SARS-CoV-2 infection can lead to hepatitis and potential liver failure.
Purpose of the Study:
- To determine the prevalence of mortality in adult COVID-19 patients with elevated hepatic profiles.
- To investigate the association between hepatic profile alterations and mortality in SARS-CoV-2 infection.
Main Methods:
- Cross-sectional, monocentric study.
- Inclusion of 91 adult patients hospitalized with confirmed COVID-19.
- Analysis of mortality rates in patients with and without elevated hepatic profiles.
Main Results:
- 61.5% of hospitalized COVID-19 patients exhibited hepatic profile alterations.
- A mortality rate of 17.6% was observed in the study cohort.
- Patients with hepatic profile alterations had a significantly higher odds ratio for mortality (OR = 12.4).
Conclusions:
- Hepatic profile alterations are prevalent in hospitalized COVID-19 patients.
- These alterations are associated with an increased risk of mortality.
- Early detection and further research are vital for improved COVID-19 patient management and prognostication.
More Related Videos
Related Concept Videos
01:22Bioavailability: Influencing Factors
Bioavailability refers to the extent and rate at which a drug reaches systemic circulation in its active form. Extent refers to the amount of the drug that makes it into circulation, while rate is the speed at which it enters circulation. It is influenced by several factors critical for optimizing drug formulations, dosing regimens, and therapeutic outcomes.Physicochemical properties of drugs and formulationsThe solubility, stability, and dissolution rate of a drug significantly impact its...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...